Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.79 |
| ▸ | MTOR | P42345 | 2/20 | 0.79 |
| ▸ | THRB | P10828 | 1/20 | 0.79 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.79 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.79 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.79 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.58 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.58 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.58 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | GMNN | O75496 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytidine SCHEMBL20241165 | 0.92 | LMNA (0.66) | LMNAMTORTHRBMDM2NCOA1 | |
| Doxecitine SCHEMBL887491 | 0.91 | DNMT1 (0.66) | LMNAMTORTHRBMDM2NCOA1 | |
| Doxecitine SCHEMBL15832461 | 0.91 | DNMT1 (0.66) | LMNAMTORTHRBMDM2NCOA1 | |
| Doxecitine SCHEMBL29910618 | 0.91 | DNMT1 (0.66) | LMNAMTORTHRBMDM2NCOA1 | |
| Doxecitine SCHEMBL23178 | 0.91 | DNMT1 (0.66) | LMNAMTORTHRBMDM2NCOA1 | |
| Doxecitine SCHEMBL23346798 | 0.91 | DNMT1 (0.66) | LMNAMTORTHRBMDM2NCOA1 | |
| Doxecitine SCHEMBL13700553 | 0.91 | DNMT1 (0.66) | LMNAMTORTHRBMDM2NCOA1 | |
| Doxecitine SCHEMBL193815 | 0.91 | DNMT1 (0.66) | LMNAMTORTHRBMDM2NCOA1 | |
| Doxecitine SCHEMBL10238960 | 0.91 | DNMT1 (0.66) | LMNAMTORTHRBMDM2NCOA1 | |
| Doxecitine SCHEMBL31503186 | 0.91 | DNMT1 (0.66) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2901160-B2 | — | — | 1999-06-07 | — | — | JP | claimed |
| EP-0577725-A4 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIV FLORIDA (US) | 1996-04-17 | — | — | EP | claimed |
| EP-0577725-A1 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1994-01-12 | — | — | EP | claimed |
| WO-2016170176-A1 | RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES | CUREVAC AG (DE) | 2016-10-27 | — | — | WO | disclosed |
| US-20160303159-A1 | A Pyrimidine Derivative and a Fatty Acid Source for Use in the Treatment of Constipation | N. V. NUTRICIA (NL) | 2016-10-20 | — | — | US | disclosed |
| EP-3076960-A1 | A PYRIMIDINE DERIVATIVE AND A FATTY ACID SOURCE FOR USE IN THE TREATMENT OF CONSTIPATION | N.V. Nutricia (NL) | 2016-10-12 | — | — | EP | disclosed |
| CN-102911166-B | The polymorph of cis-FTC and other crystal formation | 基利得科学公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-102911165-B | The polymorph of cis-FTC and other crystal formation | 基利得科学公司 | 2016-08-17 | — | — | CN | disclosed |
| WO-2015084160-A1 | A PYRIMIDINE DERIVATIVE AND A FATTY ACID SOURCE FOR USE IN THE TREATMENT OF CONSTIPATION | N.V. NUTRICIA (NL) | 2015-06-11 | — | — | WO | disclosed |
| WO-2003016572-A1 | OLIGONUCLEOTIDE THERAPEUTICS FOR TREATING HEPATITIS C VIRUS INFECTIONS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |